Level of understanding of Alzheimer disease among caregivers and the general population.

Neurología : publicación oficial de la Sociedad Española de Neurología
C JorgeG Piñol-Ripoll

Abstract

Understanding of Alzheimer disease is fundamental for early diagnosis and to reduce caregiver burden. The objective of this study is to evaluate the degree of understanding of Alzheimer disease among informal caregivers and different segments of the general population through the Alzheimer's Disease Knowledge Scale. We assessed the knowledge of caregivers in different follow-up periods (less than one year, between 1 and 5 years, and over 5 years since diagnosis) and individuals from the general population. Alzheimer's Disease Knowledge Scale scores were grouped into different items: life impact, risk factors, symptoms, diagnosis, treatment, disease progression, and caregiving. A total of 419 people (215 caregivers and 204 individuals from the general population) were included in the study. No significant differences were found between groups for overall Alzheimer's Disease Knowledge Scale score (19.1 vs. 18.8, P = .9). There is a scarce knowledge of disease risk factors (49.3%) or the care needed (51.2%), while symptoms (78.6%) and course of the disease (77.2%) were the best understood aspects. Older caregiver age was correlated with worse Alzheimer's Disease Knowledge Scale scores overall and for life impact, symptoms, treatme...Continue Reading

References

Jun 1, 1988·The Gerontologist·L DieckmannM Gatz
Nov 18, 2003·International Journal of Geriatric Psychiatry·Perla Werner
Jan 13, 2004·International Journal of Geriatric Psychiatry·Liat Ayalon, Patricia A Areán
Mar 31, 2005·International Journal of Geriatric Psychiatry·Myrra J F J Vernooij-DassenSteve Iliffe
Feb 10, 2006·International Psychogeriatrics·Huseyin A SahinHande Harmanci
Dec 29, 2006·International Journal of Geriatric Psychiatry·Nitin PurandareAlistair Burns
Jan 30, 2007·Dementia and Geriatric Cognitive Disorders·Lee-Fay Low, Kaarin Jane Anstey
Mar 29, 2007·Dementia and Geriatric Cognitive Disorders·L H Joyce YeoNeil Pendleton
Jan 31, 2008·International Journal of Geriatric Psychiatry·S CahillC Walsh
Feb 12, 2008·International Journal of Geriatric Psychiatry·Yumiko AraiSteven H Zarit
Dec 3, 2008·American Journal of Alzheimer's Disease and Other Dementias·Magda TsolakiSofia Karamavrou
Apr 14, 2009·The Gerontologist·Brian D CarpenterMargaret Gatz
May 29, 2009·Alzheimer Disease and Associated Disorders·Cathleen M ConnellDapo Akinleye
Jun 12, 2009·American Journal of Alzheimer's Disease and Other Dementias·Anna E MathewsDaniela B Friedman
Dec 16, 2010·International Journal of Geriatric Psychiatry·Naaheed MukadamGill Livingston
Jan 22, 2011·Dementia and Geriatric Cognitive Disorders·Lee-Fay LowHenry Brodaty
Aug 27, 2011·Aging & Mental Health·Lindsay N AndersonLinda K Langley
Nov 4, 2011·The Gerontologist·Perla WernerJeremia Heinik
Mar 16, 2012·Aging & Mental Health·John M HudsonSara Hobson
May 18, 2012·International Psychogeriatrics·Patricia McParlandVernon Gayle
Jan 4, 2013·BMC Geriatrics·Wendy SmythMargaret MacAndrew
Jan 12, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Anders WimoUNKNOWN Alzheimer Disease International
Mar 19, 2014·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·J Scott RobertsCathleen M Connell
Mar 29, 2014·The Journal of Nutrition, Health & Aging·A BreiningM Verny
Apr 15, 2014·Journal of Cross-cultural Gerontology·Fei SunDenise Burnette
Jul 25, 2015·Alzheimer Disease and Associated Disorders·Suzanne CahillAndrea Bobersky
Oct 28, 2015·Journal of the American Geriatrics Society·Michael J AnnearAndrew L Robinson
Feb 19, 2016·Journal of Alzheimer's Disease : JAD·Grazia D'OnofrioAntonio Greco

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Early Markers

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive and behavioral decline. Targeting markers in the earliest stages of the disease may mitigate the progression of AD. This feed focuses on early diagnosis and markers, as well as environmental, pharmacological, and drug-response biomarkers associated with this disease.